Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;8(5):588.
doi: 10.3390/jcm8050588.

New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart Failure Treatment

Diana Tint  1   2 , Roxana Florea  3 , Sorin Micu  4
Affiliations

New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart Failure Treatment

Diana Tint et al. J Clin Med. .

Abstract

(1) Background: Heart failure (HF) is a major cause of morbidity and mortality throughout the world. Despite substantial progress in its prevention and treatment, mortality rates remain high. Device therapy for HF mainly includes cardiac resynchronization therapy (CRT) and the use of an implantable cardioverter-defibrillator (ICD). Recently, however, a new device therapy-cardiac contractility modulation (CCM)-became available. (2) Aim: The purpose of this study is to present a first case-series of patients with different clinical patterns of HF with a reduced ejection fraction (HFrEF), supported with the newest generation of CCM devices. (3) Methods and results: Five patients with a left ventricular ejection fraction (LVEF) ≤ 35% and a New York Heart Association (NYHA) class ≥ III were supported with CCM OPTIMIZER® SMART IPGCCMX10 at our clinic. The patients had a median age of 67 ± 8.03 years (47-80) and were all males-four with ischemic etiology dilated cardiomyopathy. In two cases, CCM was added on top of CRT (non-responders), and, in one patient, CCM was delivered during persistent atrial fibrillation (AF). After 6 months of follow-up, the LVEF increased from 25.4 ± 6.8% to 27 ± 9%, and the six-minute walk distance increased from 310 ± 65.1 m to 466 ± 23.6 m. One patient died 47 days after device implantation. (4) Conclusion: CCM therapy provided with the new model OPTIMIZER® SMART IPG CCMX10 is safe, feasible, and applicable to a wide range of patients with HF.

Keywords: cardiac contractility modulation; cardiac devices; device implantation; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chest X-ray of a patient with a CRT device on the left side and a CCM device on the right side of the thorax. CRT: cardiac resynchronization therapy; CCM: cardiac contractility modulation.
Figure 2
Figure 2
ECG aspect of a patient supported with a cardiac resynchronization therapy and defibrillator (CRT-D) and CCM.
Figure 3
Figure 3
ECG aspect of a patient with sinus rhythm supported with an ICD and CCM.
Figure 4
Figure 4
ECG aspect of a patient with atrial fibrillation supported with an ICD and CCM.
See this image and copyright information in PMC

References

    1. Savarese G., Lund L.H. Global Public Health Burden of Heart Failure. Card. Fail. Rev. 2017;3:7–11. doi: 10.15420/cfr.2016:25:2. - DOI - PMC - PubMed
    1. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W., Andrews M.L. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl. J. Med. 2002;346:877–883. doi: 10.1056/NEJMoa013474. - DOI - PubMed
    1. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl. J. Med. 2005;352:225–237. doi: 10.1056/NEJMoa043399. - DOI - PubMed
    1. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., De Marco T., Carson P., DiCarlo L., DeMets D., White B.G., et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl. J. Med. 2004;350:2140–2150. doi: 10.1056/NEJMoa032423. - DOI - PubMed
    1. Cleland J.G., Daubert J.-C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New Engl. J. Med. 2005;352:1539–1549. doi: 10.1056/NEJMoa050496. - DOI - PubMed